Pursuant to the Agreement, JBL will manufacture and exclusively supply Tokyo-172 strain of Bacillus Calmette-Guerin ("BCG") (the "Product") to ImmunityBio
The Amendment to Sale Agreement, among other things, authorizes the issuance of an additional $459,972,480 of Shares, which were registered under the Company’s prospectus supplement dated December 23…
On March 31, 2026, Nant Capital converted $ 25.0 million of the principal of the December 2024 Convertible Promissory Note into 4,606,596 shares of common stock
the Company and Nant Capital, LLC (the “Holder”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer
ese other potential products. We expect to invest heavily in our other current product candidates and in any future product candidates that we may develop. Our product candidates are susceptible to t…
Reciprocal relationship from MRK graph: Reciprocal relationship from IBRX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from IBRX graph: Reciprocal relationship from MRK grap…
g of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort Schuyler Management Corporation Lease, dated October 1, 2021 and as amended as of the February 14, 2…
As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, a certain percentage of our net sales dur…
As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, a certain percentage of our net sales dur…
ese other potential products. We expect to invest heavily in our other current product candidates and in any future product candidates that we may develop. Our product candidates are susceptible to t…
Reciprocal relationship from MRK graph: Reciprocal relationship from IBRX graph: ese other potential products. We expect to invest heavily in our other current product candidates and in any future pr…
ImmunityBio, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IBRX-DEBT-10170
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
IBRX-DEBT-10169
Warrants outstanding: 3.24
90%
xbrl warrant detail from xbrl 2025-12-31.
IBRX-DEBT
Debt stack $1.1B
90%
Market cache reports total debt of $1.1B.
ImmunityBio, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for ImmunityBio, Inc..
ImmunityBio, Inc. Ownership
Holder
Name
Confidence
Evidence
IBRX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 396 tracked holders.
